Treatment for relapsed or refractory chronic lymphocytic leukaemia: an ongoing challenge

被引：1
作者：
Strati, Paolo [1 ]
机构：
[1] Univ Texas Houston, MD Anderson Canc Ctr, Div Canc Med, Houston, TX 77030 USA
来源：
LANCET HAEMATOLOGY | 2017年 / 4卷 / 03期
关键词：
IDELALISIB; FLUDARABINE; RITUXIMAB;
D O I：
10.1016/S2352-3026(17)30020-0
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：E97 / E98
页数：2
相关论文
共 50 条
  • [41] Rituximab, Cyclophosphamide and Dexamethasone (RCD) Chemoimmunotherapy for Relapsed Chronic Lymphocytic Leukaemia
    Simkovic, Martin
    Vodarek, Pavel
    Motyckova, Monika
    ecsiova, Dominika
    Rozsivalova, Petra
    Mocikova, Heidi
    Stepankova, Pavla
    Sykorova, Alice
    Hrochova, Katerina
    Vrbacky, Filip
    Belada, David
    Zak, Pavel
    Smolej, Lukas
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2021, 51 (04)
  • [42] Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
    Seymour, J. F.
    Kipps, T. J.
    Eichhorst, B.
    Hillmen, P.
    D'Rozario, J.
    Assouline, S.
    Owen, C.
    Gerecitano, J.
    Robak, T.
    De la Serna, J.
    Jaeger, U.
    Cartron, G.
    Montillo, M.
    Humerickhouse, R.
    Punnoose, E. A.
    Li, Y.
    Boyer, M.
    Humphrey, K.
    Mobasher, M.
    Kater, A. P.
    NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (12) : 1107 - 1120
  • [43] Venetoclax and ibrutinib for patients with relapsed/refractory chronic lymphocytic leukemia
    Niemann, Carsten U.
    Levin, Mark-David
    Dubois, Julie
    Kersting, Sabina
    Enggaard, Lisbeth
    Veldhuis, Gerrit J.
    Mous, Rogier
    Mellink, Clemens H. M.
    Dobber, Johan A.
    Poulsen, Christian B.
    Frederiksen, Henrik
    Janssens, Ann
    Schjodt, Ida
    Dompeling, Ellen C.
    Ranti, Juha
    Mattsson, Mattias
    Bellido, Mar
    Tran, Hoa T. T.
    Nasserinejad, Kazem
    Kater, Arnon P.
    BLOOD, 2021, 137 (08) : 1117 - 1120
  • [44] Ofatumumab and high-dose methylprednisolone for the treatment of patients with relapsed or refractory chronic lymphocytic leukemia
    Castro, J. E.
    Choi, M. Y.
    Carvajal, T.
    Almahasnah, E.
    Chang, J.
    James, D. F.
    Kipps, T. J.
    BLOOD CANCER JOURNAL, 2014, 4 : e258 - e258
  • [45] Phase II Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Treatment-Naive and Relapsed or Refractory Chronic Lymphocytic Leukemia
    Rogers, Kerry A.
    Huang, Ying
    Ruppert, Amy S.
    Abruzzo, Lynne V.
    Andersen, Barbara L.
    Awan, Farrukh T.
    Bhat, Seema A.
    Dean, Allison
    Lucas, Margaret
    Banks, Christin
    Grantier, Cara
    Heerema, Nyla A.
    Lozanski, Gerard
    Maddocks, Kami J.
    Valentine, Thomas R.
    Weiss, David M.
    Jones, Jeffrey A.
    Woyach, Jennifer A.
    Byrd, John C.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (31) : 3626 - +
  • [46] Flavopiridol treatment of patients aged 70 or older with refractory or relapsed chronic lymphocytic leukemia is a feasible and active therapeutic approach
    Stephens, Deborah M.
    Ruppert, Amy S.
    Blum, Kristie
    Jones, Jeffrey
    Flynn, Joseph M.
    Johnson, Amy J.
    Ji, Jia
    Phelps, Mitch A.
    Grever, Michael R.
    Byrd, John C.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2012, 97 (03): : 423 - 427
  • [47] Rituximab plus cladribine with or without cyclophosphamide in patients with relapsed or refractory chronic lymphocytic leukemia
    Robak, Tadeusz
    Smolewski, Piotr
    Cebula, Barbara
    Grzybowska-Izydorczyk, Olga
    Blonski, Jerzy Z.
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2007, 79 (02) : 107 - 113
  • [48] Examining the medical resource utilization and costs of relapsed and refractory chronic lymphocytic leukemia in Ontario
    Hassan, S.
    Seung, S. J.
    Cheung, M. C.
    Fraser, G.
    Kuriakose, B.
    Trambitas, C.
    Mittmann, N.
    CURRENT ONCOLOGY, 2017, 24 (01) : E50 - E54
  • [49] Prognostic risk score for patients with relapsed or refractory chronic lymphocytic leukaemia treated with targeted therapies or chemoimmunotherapy: a retrospective, pooled cohort study with external validations
    Soumerai, Jacob D.
    Ni, Ai
    Darif, Mohamed
    Londhe, Anil
    Xing, Guan
    Mun, Yong
    Kay, Neil E.
    Shanafelt, Tait D.
    Rabe, Kari G.
    Byrd, John C.
    Chanan-Khan, Asher A.
    Furman, Richard R.
    Hillmen, Peter
    Jones, Jeffrey
    Seymour, John F.
    Sharman, Jeffrey P.
    Ferrante, Lucille
    Mobasher, Mehrdad
    Stark, Thomas
    Reddy, Vijay
    Dreiling, Lyndah K.
    Bhargava, Pankaj
    Howes, Angela
    James, Danelle F.
    Zelenetz, Andrew D.
    LANCET HAEMATOLOGY, 2019, 6 (07): : E366 - E374
  • [50] Results of a phase II study of lenalidomide and rituximab for refractory/relapsed chronic lymphocytic leukemia
    Chavez, Julio C.
    Piris-Villaespesa, Miguel
    Dalia, Samir
    Powers, John
    Turba, Elyce
    Nodzon, Lisa
    Komrokji, Rami
    Sokol, Lubomir
    Locke, Frederick L.
    Lancet, Jeffrey
    Sotomayor, Eduardo M.
    Kharfan-Dabaja, Mohamed A.
    Pinilla-Ibarz, Javier
    LEUKEMIA RESEARCH, 2016, 47 : 78 - 83
12345